Managing the multifaceted nature of type 2 diabetes using once‐weekly injectable GLP‐1 receptor agonist therapy

WHAT IS KNOWN AND OBJECTIVE: As a highly prevalent chronic condition associated with complications and high mortality rates, it is important for pharmacists to have a comprehensive understanding of the impact of type 2 diabetes (T2D) and available treatment options. The use of injectable glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) is recommended as an effective and convenient treatment regimen for improving glycaemic control in individuals with T2D, with a good safety profile; however, the wider extent of its potential benefits often are unknown to clinical pharmacists. The objective of this article is to provide an overview of the impact of T2D on individuals and to discuss the multifaceted role of once‐weekly (QW) GLP‐1 RAs in addressing these challenges. METHODS: This is a narrative review of the published literature regarding the use of injectable GLP‐1 RAs in managing health complications in people with T2D. RESULTS AND DISCUSSION: Recent findings reveal additional benefits of GLP‐1 RAs in managing T2D complications, including atherosclerotic cardiovascular (CV) disease, retinopathy, neuropathy, and nephropathy. Dulaglutide and semaglutide have been shown to provide additional CV benefit in patients at high risk of CV events compared with standard of care/placebo and may offer renal protection in patients with chronic kidney disease. Cost‐effectiveness studies, taking into consideration these different complications, have shown that QW GLP‐1 RAs were cost‐effective compared with other therapies. GLP‐1 RAs may also help to improve overall health‐related quality of life, reducing the risk of depression and 'diabetes distress', and limiting the risk of hypoglycaemia. WHAT IS NEW AND CONCLUSION: From the literature, this appears to be the first review of the evidence supporting the multifaceted role of QW GLP‐1 RAs in T2D, with particular emphasis on their use in comorbid conditions, as well as associated potential financial and well‐being benefits. The results suggest that QW GLP‐1 RAs may be an attractive treatment option for improving glycaemic control in T2D, especially in individuals with (or at risk of) additional comorbidities or health complications.